Abstract:Historically, lack of data on cost-effectiveness of influenza vaccination has been identified as a barrier to vaccine use in low- and middle-income countries. We conducted a systematic review of economic evaluations describing (1) costs of influenza illness; (2) costs of influenza vaccination programs; and (3) vaccination cost-effectiveness from low- and middle-income countries to assess if gaps persist that could hinder global implementation of influenza vaccination programs. We performed a systematic search in Medline, Embase, Cochrane Library, CINAHL, and Scopus in January 2022 and October 2023 using a combination of the following key words: "influenza" AND "cost" OR "economic." The search included studies with publication years 2012 through 2022. Studies were eligible if they (1) presented original, peer-reviewed findings on cost of illness, cost of vaccination program, or cost-effectiveness of vaccination for seasonal influenza; and (2) included data for at least 1 low- or middle-income country. We abstracted general study characteristics and data specific to each of the 3 study types. Of 54 included studies, 26 presented data on cost-effectiveness, 24 on cost-of-illness, and 5 on program costs. Represented countries were classified as upper-middle income (UMIC; n = 12), lower-middle income (LMIC; n = 7), and low-income (LIC; n = 3). The most evaluated target groups were children ( n = 26 studies), older adults ( n = 17), and persons with chronic medical conditions ( n = 12); fewer studies evaluated pregnant persons ( n = 9), healthcare workers ( n = 5), and persons in congregate living settings ( n = 1). Costs-of-illness were generally higher in UMICs than in LMICs/LICs; however, the highest national economic burden, as a percent of gross domestic product and national health expenditure, was reported from an LIC. Among studies that evaluated the cost-effectiveness of influenza vaccine introduction, most (88%) interpreted at least 1 scenario per target group as either cost-effective or cost-saving, based on thresholds designated in the study. Key limitations of this work included (1) heterogeneity across included studies; (2) restrictiveness of the inclusion criteria used; and (3) potential for missed influenza burden from use of sentinel surveillance systems. The 54 studies identified in this review suggest an increased momentum to generate economic evidence about influenza illness and vaccination from low- and middle-income countries during 2012 to 2022. However, given that we observed substantial heterogeneity, continued evaluation of the economic burden of influenza illness and costs/cost-effectiveness of influenza vaccination, particularly in LICs and among underrepresented target groups (e.g., healthcare workers and pregnant persons), is needed. Use of standardized methodology could facilitate pooling across settings and knowledge sharing to strengthen global influenza vaccination programs.

Hospitalizations and emergency attendance averted by influenza vaccination in Victoria, Australia, 2017 – 2019

Estimated Influenza Illnesses and Hospitalizations Averted by Influenza Vaccination among Children Aged 6-59 Months in Suzhou, China, 2011/12 to 2015/16 Influenza Seasons

Reduction of Influenza Disease Cost with Suboptimal Vaccination

Cost-effectiveness study on influenza prevention in Hong Kong

Public health and economic benefits of seasonal influenza vaccination in risk groups in France, Italy, Spain and the UK: state of play and perspectives

The economic burden of influenza-associated outpatient visits and hospitalizations in China: a retrospective survey

Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023

Influenza Hospitalization Burden by Subtype, Age, Comorbidity, and Vaccination Status: 2012-2013 to 2018-2019 Seasons, Quebec, Canada

Estimating historical disease burden and the impact of vaccination by influenza type and subtype in the United States, 2016-2020

Cost-Effectiveness of Influenza Vaccination in Healthy Children: A 10-Year Population-Based Study

Influenza Vaccine Effectiveness in Preventing Hospitalization among Beijing Residents in China, 2013-15.

Costs and cost-effectiveness of influenza illness and vaccination in low- and middle-income countries: A systematic review from 2012 to 2022

ATAGI targeted review 2023: Vaccination for preventing influenza in Australia

Optimising age coverage of seasonal influenza vaccination in England: A mathematical and health economic evaluation

The association between influenza vaccination uptake and influenza and pneumonia-associated deaths in the United States

An Effect and Cost-Benefit Analysis of Influenza Vaccine among the Healthcare Worker

Influenza Epidemiology and Influenza Vaccine Effectiveness During the 2016–2017 Season in the Global Influenza Hospital Surveillance Network (GIHSN)

The Effectiveness of Influenza Vaccination in Preventing Hospitalizations in Elderly in Beijing, 2016-18

Impact of national influenza vaccination strategy in severe influenza outcomes among the high-risk Portuguese population

Cost-benefit of Influenza Vaccinations in Frontline Workers: A Dynamic Modelling Study

Burden of seasonal influenza in the Swiss adult population during the 2016/2017-2018/2019 influenza seasons